iCAD to Showcase ProFound AI™ Solution for Digital Breast Tomosynthesis at ECR 2019
Currently pending CE Mark, ProFound AI technology for 2D mammography will
also be previewed
Nashua, NH – (Feb. 21,
2019) – iCAD,
Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced
that it will present its latest artificial intelligence software solution for digital breast tomosynthesis
(DBT), ProFound
AI™, in the iCAD
exhibition booth (Expo X1, Booth AI-17) during the European Congress
of Radiology (ECR) 2019, the second-largest radiological meeting in the world. Held
by the European Society of Radiology, the conference will take place February 27-March
3, 2019, in Vienna, Austria.
ProFound
AI is a high-performance, deep-learning, cancer detection and workflow solution
for DBT. This transformational technology delivers critical benefits to
radiologists, their facilities and patients through the improvement of
cancer detection rates by an average of 8 percent and a reduction in the rate
of unnecessary patient recalls by an average of 7 percent. The technology is designed
to detect malignant soft-tissue densities and calcifications and provides
radiologists with the certainty of finding lesion and case scores.
“With growing global demand for cancer detection and workflow solutions
built on the latest advances in deep-learning, we are thrilled to demonstrate
the unrivaled capabilities of our ProFound AI solution, which is clinically
proven to help clinicians detect more cancers, decrease false positives and reduce
recalls and reading time,” said Stacey Stevens, Executive Vice President and
Chief Strategy and Commercial Officer at iCAD. “ProFound AI offers tremendous benefits
to radiologists and their patients in identifying cancer earlier. We look
forward to expanding the unique capabilities of our algorithm through new
application areas, including breast cancer risk prediction, in the future.”
Complementing ProFound AI for DBT, iCAD will also preview ProFound AI
for 2D mammography, which is currently pending CE mark. In
addition, iCAD will lead two clinical presentations during the conference and host
an event entitled, “AI After Dark.”
iCAD clinical presentations at ECR 2019:
- Thursday, February 28th
12:00 – 13:00 CET
Voice of EPOS Stage 4
Jeff Hoffmeister, MD, Vice President and Medical
Director at iCAD
“Case Examples to Demonstrate Positive and
Negative Impacts of a Deep Learning Based Concurrent Artificial Intelligence
System for Digital Breast Tomosynthesis”
- Friday, March 1st
13:50 CET
Artificial Intelligence Theatre
Senthil Periaswamy, PhD, Vice President of
Research at iCAD
“How AI Can Improve Diagnostic Performance and
Reduce Reading Time in Breast Tomosynthesis”
iCAD’s AI After Dark event will be an evening reception on Friday, March
1, at 18:00 CET at DO & CO Hotel Vienna. During the program titled, “New
Frontier: Predicting Breast Cancer through AI,” clinical leaders will discuss
their perspectives on how the Company’s solutions are transforming breast
cancer detection, share their personal experiences with ProFound AI in research
and clinical practice and detail their vision for risk assessment.
Distinguished speakers will include:
- Per Hall, MD, Professor/Senior
Physician, Karolinska Institutet; speaking on “Risk stratified approach to
breast cancer screening.” - Sylvia H.
Heywang-Köbrunner, MD, Head of Reference Center Mammography Munich, Head of
Brustdiagnostik Munich, Head of FFB gGmbH; speaking on “ProFound AI Experience:
500 consecutive screen detected abnormalities.” - •Axel Gräwingholt, MD, Radiologist,
Radiologie am Theater; speaking on “Experience with
Profound AI in private practice.”
For
more information about iCAD and its solutions or to register for a meeting or
demonstration at ECR, please visit www.icadmed.com/ecr2019.html.
About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, product market acceptance, possible technological obsolescence of
products, increased competition, litigation and/or government regulation,
changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a
decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”,
“consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”,
“seek”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, including the 10-K for the year ended December 31, 2018,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568